Eversense® CGM+RPM solution to be powered by
Rimidi’s clinical management platform
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) systems
for people with diabetes, today announced a strategic partnership
with Rimidi, a leading clinical management platform designed to
optimize clinical workflows, enhance patient experiences, and
achieve quality objectives for chronic disease management, in the
development of its Eversense® Remote Patient Monitoring (RPM)
Program for use by the health care providers.
“We are excited to combine our clinical management platform with
Senseonics’ technology. Our platform and its capabilities were
designed to leverage the data from medical devices like Eversense
CGM to streamline and improve chronic disease management,” said
Chief Executive Officer of Rimidi, Lucienne Ide, MD, PhD. “81% of
patients with type 2 diabetes do not meet their HbA1c, blood
pressure and cholesterol goals, and this partnership represents an
exciting opportunity to assist providers in driving improved
glucose outcomes for this population.”
The partnership will integrate Eversense glucose data into
Rimidi's comprehensive clinical management platform used by health
systems, capitated health plans and physician practices. Rimidi's
platform aligns with Medicare’s reimbursable remote patient
monitoring telehealth programs while seamlessly integrating within
existing Electronic Health Record (EHR) systems, supporting quality
improvement initiatives, driving workflow optimization, increasing
patient engagement and providing clinical decision support.
Powered by Rimidi, the Eversense CGM + RPM solution is intended
to seamlessly and securely push patient glucose data to the most
widely used EHR systems, to provide direct access for healthcare
providers. With increased visibility on glucose trends, high or low
event frequency, and time-in-range statistics, providers will be
able to proactively engage patients to provide lifestyle and
therapy optimization guidance in order to better manage their
diabetes, lower healthcare costs and improve clinical outcomes.
“The Eversense RPM Program™ is the next step in our roadmap to
combine long-term implantable CGM technology with advanced
analytics and personalized health services into a comprehensive
diabetes solution. Eversense RPM will arm providers with powerful
data to optimize care in between office visits where 99% of
diabetes management takes place,” said Tim Goodnow, PhD, President
and Chief Executive Officer of Senseonics. “Rimidi’s best-in-class
platform will seamlessly integrate Eversense data. Combined with
expert diabetes nurse counselors, proprietary decision support
protocols, and fully compliant RPM reimbursement infrastructure,
our Eversense CGM+RPM solution is intended to further differentiate
Eversense from other CGM manufacturers, reaching beyond a
stand-alone device and putting a comprehensive solution into the
hands of health care systems, providers, and patients. Aligned with
Medicare’s diabetes population management initiatives, we are proud
to be at the forefront of providing the next evolution of
innovation in diabetes with the goal to give healthcare
professionals the confidence of knowing patients have support
outside of their office and patients the confidence of achieving
healthy outcomes. We look forward to providing Ascensia, our
commercial partner, with this exciting program, offering further
reason for providers and patients to choose Eversense.”
Senseonics, in collaboration with its commercial partner,
Ascensia Diabetes Care, intends to make the Eversense CGM+RPM
solution available to select population health-based systems
beginning in the third quarter of 2024, followed by a planned
expansion of the program to all healthcare prescribers and users of
Eversense.
Potential Eversense users can go to
www.ascensiadiabetes.com/eversense to learn more about Eversense.
Physicians, nurse practitioners and physician assistants who are
interested in offering the Eversense CGM System can sign up at
https://www.ascensiadiabetes.com/eversense/become-a-provider/.
Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more
about the first and only long-term implantable CGM system.
† There is no glucose data generated when the transmitter is
removed
1 Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin
delivery: benefits, challenges, and recommendations. A Consensus
Report of the Joint Diabetes Technology Working Group of the
European Association for the Study of Diabetes and the American
Diabetes Association. Diabetologia. 2023;66(1):3-22.
doi:10.1007/s00125-022-05744-z
2 Garg S. et al. Evaluation of Accuracy and Safety of the
Next-Generation Up to 180-Day Long-Term Implantable Eversense
Continuous Glucose Monitoring System: The PROMISE Study. Diabetes
Technology & Therapeutics 2021; 24(2): 1-9.DOI:
10.1089/dia.2021.0182
3 Barnard KD, Kropff J, Choudhary P, et al. Acceptability of
Implantable Continuous Glucose Monitoring Sensor. J Diabetes Sci
Technol. 2018;12(3):634-638. doi:10.1177/1932296817735123
4 Boscari F, Vettoretti M, Cavallin F, et al. Implantable and
transcutaneous continuous glucose monitoring system: a randomized
cross over trial comparing accuracy, efficacy and acceptance. J
Endocrinol Invest. 2022;45(1):115-124.
doi:10.1007/s40618-021-01624-2
5 Hanson K, Kipnes M, Tran H. Comparison of Point Accuracy
Between Two Widely Used Continuous Glucose Monitoring Systems. J
Diabetes Sci Technol. Published online January 8, 2024.
doi:10.1177/19322968231225676
6 Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective
Multicenter Evaluation of the Accuracy of a Novel Implanted
Continuous Glucose Sensor: PRECISE II. Diabetes Technol Ther.
2018;20(3):197-206. doi:10.1089/dia.2017.0142
7 Eversense E3 User Manual LBL-4002-01-001 Rev B 02/2022
About Eversense
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels for up to 180
days in persons with diabetes age 18 and older. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration primarily one time
a day after day 21, and when symptoms do not match CGM information
or when taking medications of the tetracycline class. The sensor
insertion and removal procedures are performed by a health care
provider. The Eversense E3 CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://www.ascensiadiabetes.com/eversense/safety-info/.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology
company focused on the development and manufacturing of glucose
monitoring products designed to transform lives in the global
diabetes community with differentiated, long-term implantable
glucose management technology. Senseonics' CGM system Eversense® E3
includes a small sensor inserted completely under the skin that
communicates with a smart transmitter worn over the sensor. The
glucose data are automatically sent every 5 minutes to a mobile app
on the user's smartphone.
About Rimidi
Created by doctors, for doctors, Rimidi is a digital health
company that supports healthcare providers in the delivery of
remote patient monitoring and chronic disease management with
EHR-integrated software, services, and connected devices. By
combining clinical data from the EHR with data from connected
devices and patient surveys, Rimidi presents a complete picture of
the patient and supports care delivery across the continuum from
the clinic to the home to allow for proactive, guideline-based
management and prioritization of highest-need patients. For more
information, visit rimidi.com and follow us on X, formerly known as
Twitter, and LinkedIn.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements about the
patient and provider experience, statements regarding launch
expectations of the Eversense RPM solution, statements regarding
the benefits of pursuing a new strategic partnership with Rimidi,
statements regarding the attributes and value to patients and
providers of Eversense RPM, statements regarding the design and
implementation of Eversense RPM, and other statements containing
the words “believe,” “expect,” “intend,” “may,” “projects,” “will,”
“planned,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: uncertainties inherent in the
commercial launch and commercial expansion of the Eversense product
and a new RPM solution, uncertainties inherent in the transition of
commercialization responsibilities to Ascensia Diabetes Care and
its commercial initiatives, uncertainties inherent in the
development of new technology, uncertainties inherent in finalizing
integration and commercial terms with a new partner, and such other
factors as are set forth in the risk factors detailed in
Senseonics’ Annual Report on Form 10-K for the year ended December
31, 2023 and Senseonics’ other filings with the SEC under the
heading “Risk Factors.” In addition, the forward-looking statements
included in this press release represent Senseonics’ views as of
the date hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics’ views to change. However, while
Senseonics may elect to update these forward-looking statements at
some point in the future, Senseonics specifically disclaims any
obligation to do so except as required by law. These
forward-looking statements should not be relied upon as
representing Senseonics’ views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509372795/en/
Senseonics Investor Contact Philip Taylor Gilmartin Group
415-937-5406 Investors@senseonics.com
Senseonics (AMEX:SENS)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Senseonics (AMEX:SENS)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024